Pseudohypoxia, mitochondrial mutations, the Warburg effect, and cancer

Biomedical Research

Volumn 23, Issue SPEC. ISSUE, 2012, Pages 109-131

  Sanders, Edward ^a  

^a NONE   (Switzerland)

Author keywords

Cancer; Epidemiology; Mitochondrial mutations; Pseudohypoxia; Von hippel lindau syndrome; Warburg effect

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA;

AEROBIC METABOLISM; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESEARCH; CANCER RISK; CARCINOGENESIS; CELL METABOLISM; CITRIC ACID CYCLE; CLEAR CELL CARCINOMA; FUMARATE HYDRATASE GENE; GENE TARGETING; GLYCOLYSIS; HUMAN; HYPOXIA; ISOCITRATE DEHYDROGENASE GENE; KIDNEY CARCINOMA; LEIOMYOMATOSIS; MISSENSE MUTATION; MITOCHONDRIAL GENETICS; MUTATIONAL ANALYSIS; NONHUMAN; NONSENSE MUTATION; PHEOCHROMOCYTOMA; SUCCINATE DEHYDROGENASE GENE; TUMOR GENE; VON HIPPEL LINDAU DISEASE; VON HIPPEL LINDAU GENE;

EID: 84857145528     PISSN: 0970938X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (111)

1. Massey MN. 2002. Overview of clinical PET. Br J Radiol 2002; 75: S1-S5.
2. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nature Rev Cancer 2004; 4: 891-899.
3. Ortega AD, Sanchez-Arago M, Giner-Sanchez D, Sanchez-Cenizo L, Willers I, Cuezva JM. Glucose avidity of carcinomas. Cancer Lett 2009; 276: 125-135.
4. Gambhir SS, Czernin J, Schwimmer J, Silverman DHS, Coleman RE. Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med 2001; 42 (5 Suppl): 1S-93S.
5. Altenberg B, Greulich KO. Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics 2004; 84: 1014-1020.
6. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009. 324: 1029-1033.
7. Feron O. Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells. Radiother Oncol 2009; 92: 329-333.
8. Cairns RA, Harris IS, Mak TW. 2011. Regulation of cancer cell metabolism. Nat Review Cancer, 11: 85-95.
9. Dang CV, Hamaker M, Sun P, Le A, Gao P. Therapeutic targeting of cancer cell metabolism. J Mol Med (Berl) 2011; 89: 205-212.
10. Lopez-Lazaro M. The Warburg effect: why and how do cancer cells activate glycolysis in the presence of oxygen? Anticancer Agents Med Chem 2008. 8: 305-312.
11. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 2008; 13: 472-482.
12. Mazurek S. Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. Int J Biochem Cell Biol 2011; 43: 969-980.
13. Wittwer JA, Robbins D, Wang F, Codarin S, Shen X, Kevil CG, Huang TT, Van Remmen H, Richardson A, Zhao Y. Enhancing mitochondrial respiration suppersses tumor promoter TPA-induced PKM2 expression and cell transformation in skin epidermal JB6 cells. Cancer Prev Res (Phila) 2011;. 4: 1476-1484.
14. Mazurek S, Grimm H, Boschek CB, Vaupel P, Eigenbrodt E. Pyruvate kinase type M2: a crossroad in the tumor metabolome. Br J Nutr 2002; 87 Suppl. 1: S23-S39.
15. Mazurek S, Bosheck CB, Hugo F, Eigenbrodt E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol 2005; 15: 300-308.
16. Mazurek S. Pyruvate kinase type M2: a key regulator within the tumour metabolome and a tool for metabolic profiling of tumours. Ernst Schering Found Symp Proc 2007; (4): 99-124.
17. Warburg O. On the origin of cancer cells. Science 1956; 123: 309-314.
18. Koppenol WH, Bounds PL, Dang CV. Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer 2011; 11: 325-337.
19. Majmundar AJ, Wong WJ, Simon MC. Hypoxia inducible factors and the response to hypoxic stress. Mol Cell 2010; 40: 294-309.
20. Stubbs M, Griffiths JR. The altered metabolism of tumors: HIF-1 and its role in the Warburg effect. Adv Enzyme Regul 2010; 50: 44-55.
21. Kim JJ, Rini BI, Hansel DE. 2010. Von Hippel Lindau syndrome. Adv Exp Med Biol 2010; 685: 228-249.
22. Hoffman MA, Ohh M, Yang H, Klco JM, Ivan M, Kaelin WG Jr. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum Mol Genet 2001.; 10: 1019-1027
23. Lee S, Nakamura E, Yang H, Wei W, Linggi MS, Sajan MP, Farese RV, Freeman RS, Carter BD, Kaelin WG Jr, Schlisio S. Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell 2005; 8: 155-167.
24. Kaelin WG Jr. Treatment of kidney cancer: insights provided by the VHL tumor-suppressor protein. Cancer 2009.; 115 (10 Suppl): 2262-2272.
25. Bratslavsky G, Sudarshan S, Neckers L, Linehan WM. Pseudohypoxic pathways in renal cell carcinoma. Clin Cancer Res 2007; 13: 4667-4671.
26. Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin WG Jr. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell. 2002;: 237-246.
27. Semenza GL. HIF-1 mediates the Warburg effect in clear cell renal carcinoma. J Bioenerg Biomembr 2007;39: 231-234.
28. Marin-Hernandez A, Gallardo-Perez JC, Ralph SJ, Rodriquez-Enriquez S, Moreno-Sanchez R. HIF-1alpha modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms. Mini Rev Med Chem 2009; 9: 1084-1101.
29. Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 2008;. 8: 705-713.
30. McFate T, Mohyelden A, Lu H, Thakar J, Henriques J, Halim ND, Wu H, Schell MJ, Tsang TM, Teahan O, Zhou S, Califano JA, Jeoung NH, Harris RA, Verma A. Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells. J Biol Chem 2008; 283: 22700-22708.
31. Smolkova K, Plecita-Hlavata L, Bellance N, Benard G, Rossignol R, Jezek P. Waves of gene regulation sup press and then restore oxidative phosphorylation in cancer cells. Int J Biochem Cell Biol 2011; 43: 950-968.
32. Perez JX, Roig T, Manzano A, Dalmau M, Boada J., Ventura F, Rosa JL, Bermudez J, Bartrons R. Overexpression of fructose 2,6-bisphosphatase decreases glycolysis and delays cell cycle progression. Am J. Physiol Cell Physiol 2000; 279: C1359-C1365.
33. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL, Cantley LC. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008; 452: 230-233.
34. Christofk HR, Vander Heiden MG, Wu N, Asara JM, Cantley LC. Pyruvate kinase M2 is a phosphotyrosinebinding protein. Nature 2008; 452: 181-186.
35. Semenza GL. Regulation of metabolism by hypoxiainducible factor 1. Cold Spring Harb Symp Quant Biol 2011; 22. [Epub ahead of print].
36. Barontini M, Dahia PLM. VHL disease. Best Pract Res Clin Endocrinol Metab 2010; 24: 401-413.
37. Turner KJ, Moore JW, Jones A, Taylor CF, Cuthbert-Heavens D, Han C, Leek RD, Gatter KC, Maxwell PH, Ratcliffe PJ, Cranston D, Harris AL. Expression of hypoxia-inducible factors in human renal cell cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res 2002; 62: 2957-2961.
38. Boedeker CC, Erlic Z, Richard S, Kontny U, Giminez-Roqueplo AP, Cascon A, Robledo M, de Campos JM, van Nederveen FH, de Krijger RR, Burnichon N, Gaal J, Walter MA, Reschke K, Wiech T, Weber J, Rückauer K, Plouin PF, Darrouzet V, Giraud S, Eng C, Neumann HPH Head and neck paragangliomas in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. J Clin Endrocinol Metab 2009; 94: 1938-1944.
39. Li M, Kim WY. Two sides to every story: the HIFdependent and HIF-independent functions of pVHL. J Cell Mol Med 2011; 15: 187-195.
40. Calzada MJ. Von Hippel-Lindau syndrome: molecular mechanisms of the disease. Clin Transl Oncol 2010; 12: 160-165.
41. Maher ER, Yates JRW, Harries R, Benjamin C, Harris R, Moore AT, Ferguson-Smith MA. Clinical features and natural history of von Hippel-Liindau disease. Q J Med 1990; 77: 1151-1163.
42. Clifford SC, Cockman ME, Smallwood AC, Mole DR, Woodward ER, Maxwell PH, Ratcliffe PJ, Maher ER. Contrasting effects on HIF-1α regulation by diseasecausing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum Mol Genet 2001; 10: 1029-1038.
43. Ong KR, Woodward ER, Killick P, Lim C, Macdonald F, Maher ER. Genotype-phenotype correlations in von Hippel-Lindau disease. Hum Mutat 2007; 28: 143-149.
44. Maranchie JK, Vassselli R, Riss J, Bonifacino JS, Linehan WM, Klausner RD. The contribution of VHL substrate binding HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 2002; 1: 247-255.
45. Gordan JD, Lal P, Dondeti VR, Letrero F, Parekh KN, Oquendo CE, Greenberg RA, Flaherty KT, Rathmell WK, Keith B, Simon MC, Nathanson KL. HIF-1α effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 2008; 14: 435-446.
46. Unwin RD, Craven RA, Harnden P, Hanrahan S, Totty N, Knowles M, Eardley I, Selby PJ, Banks RE. Proteomic changes in renal cancer and co-ordinate emonstration of both the glycolytic and mitochondrial aspects of the Warburg effect. Proteomics 2003; 3: 1620-1632.
47. Hu CJ, Wang LY, Chodosh LA, Keith B, Simon MC. Differential roles of hypoxia-inducible factor 1a (HIF-1α) and HIF-2α in hypoxic gene regulation. Mol Cell Biol 2003; 23: 9361-9374.
48. Wang V, Davis DA, Haque M, Huang LE, Yarchoan R. Differential gene up-regulation by hypoxia-inducible factor-1a and hypoxia-inducible factor-2a in HEK293T cells. Cancer Res 2005; 65: 3299-3306.
49. Zhang H, Gao P, Fukuda R, Kumar G, Krishnamachary B, Zeller KI, Dang CV, Semenza GL. HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of CMYC activity. Cancer Cell 2007; 11: 407-420.
50. Choi H, Chun YS, Kim TY, Park JW. HIF-2alpha enhances beta-catenin/TCF-driven transcription by interacting with beta-catenin. Cancer Res 2010; 70: 10101-10111.
51. Abdulrahman M, Maina EN, Morris MR, Zatyka M, Raval RR, Banks RE, Wiesener MS, Richards FM, Johnson CM, Latif F, Maher ER. Identification of novel VHL targets that are associated with the development of renal cell carcinoma. Oncogene 2007; 26: 1661-1672.
52. Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F, Giaccia AJ, Abraham RT. Regulation of hypoxia-inducible factor 1a expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002; 22: 7004-7014.
53. Toschi A, Lee E, Gadir N, Ohh M, Foster DA. Differential dependence of hypoxia-inducible factors 1a and 2a on mTORC1 and mTORC2. J Biol Chem 2008; 283: 34495-34499.
54. Wysocki PJ. mTOR in renal cell cancer: modulator of tumor biology and therapeutic target. Expert Rev Mol Diagn 2009; 9: 231-241.
55. An J, Rettig MB. Mechanism of von Hippel-Lindau protein-mediated suppression of nuclear factor kappa B activity. Mol Cell Biol 2005; 25: 7546-7556.
56. Brauch H, Kisshida T, Glavac D, Chen F, Pausch F, Höfler H, Latif F. Lerman MI, Zbar B, Neumann HP. von Hippel-Lindau (VHL) disease with pheochromocytoma in the Black Forest region of Germany: evidence for a founder effect. Hum Genet 1995; 95: 551-556.
57. Neumann HP, Eng C, Mulligan LM, Glavac D, Zäuner I, Ponder BA, Crossey PA, Maher ER, Brauch H. Consequences of direct genetic testing for germline mutations in the clinical management of families with multiple endocrine neoplasia, type II. JAMA 1995; 274: 1149-1151.
58. Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, Pavletich N, Chau V, Kaelin WG. Ubiquitination of HIF requires direct binding to the von Hippel- Lindau protein b-domain. Nat Cell Biol 2000; 2: 423-427.
59. Cervera AM, Apostolova N, Crespo FL, Mata M, McCreath KJ. Cells silenced for SDHB expression display characteristic features of the tumor phenotype. Cancer Res 2008; 68: 4058-4067.
60. Favier J, Brière JJ, Burnichon N, Rivière J, Vescovo L, Benit P, Giscos-Douriez, I, De Reyniès A, Bertherat J, Badoual C, Tissier F, Amar L, Libé R, Plouin PF, Jeunemaitre X, Rustin P, Giminez-Roqueplo AP. The Warburg effect is genetically determined in inherited pheochromocytomas. PLoS One 2009; 4: e7904.
61. Havekes B, King K, Lai EW, Romjin JA, Corssmit EPM, Pacak K. New imaging approaches to pheochromocytomas and paragangliomas. Clin Endocrinol (Oxf) 2010; 72: 137-145.
62. Kanotrovich V, King KS, Pacak K. SDH-related pheochromocytoma and paraganglioma. Best Pract Res Clin Endocrinol Metab 2010; 24: 415-424.
63. Burnichon N, Brière JJ, Libé R, Vescovo L, Rivière J, Tissier F, Jouanno E, Jeunemaitre X, Bénit P, Tzagoloff A, Rustin P, Bertherat J, Favier J, Gimenez-Roqueplo AP. SDHA is a tumor suppressor gene causing paraganglioma. Hum Mol Genet 2010. 19: 3011-3020.
64. Bardella C, Pollard PJ, Tomlinson I. SDH mutations in cancer. Biochim Biophys Acta 2011; 1807: 1432-1443.
65. Raygada M, Pasini B, Stratakis CA. 2011. Hereditary paragangliomas. Adv Otorhinolaryngol, 70: 99-106.
66. Maher ER. Genetics of familial renal cancers. Nephron Exp Neprhol 2011; 118: e21-e26.
67. Ricketts CJ, Forman JR, Rattenberrry E, Bradshaw N, Lalloo F, Izatt L, Cole TR, Armstrong R, Kumar VK, Morrison PJ, Atkinson AB, Douglas F, Ball SG, Cook J, Srirangalingam U, Killick P, Kirby G, Aylwin S, Woodward ER, Evans DGR, Hodgson SV, Murday V, Chew SL, Connell JM, Blundell TL, MacDonald F, Maher ER. Tumor risks and genotype-phenotypeproteotype analysis in 358 patients with germline mutations in SDHB and SDHD. Hum Mutat 2009; 31: 41-51.
68. Dahia PLM, Ross KN, Wright ME, Hayashida CY, Santagata S, Barontini M, Kung AL, Sanso G, Powers JF, Tischler AS, Hodin R, Heitritter S, Moore F Jr, Dluhy R, Sosa JA, Ocal IT, Benn DE, Marsh DJ, Robinson BG, Schneider K, Garber J, Arum SM, Korbonits M, Grossman A, Pigny P, Toledo SPA, Nosé V, Li C, Stiles CD. A HIF1α regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet 2005; 1: 72-80.
69. Lopez-Jiminez E, Gomez-Lopez G, Leandro-Garcia LJ, Munoz I, Schiavi F, Montero-Conde C, de Cubas AA, Ramires R, Landa I, Leskela S, Maliszewska A, Inglada-Perrez L, de la Vega L, Rodriguez-Antona C, Leton R, Bernal C, de Campos JM, Diez-Tascon C, Fraga MF, Boullosa C, Pisano DG, Opocher G, Robledo M, Cascon A. Research resource: transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas. Mol Endocrinol 2010; 24: 2382-2391.
70. Bayley JP, Devilee P. Warburg tumours and the mechanism of mitochondrial tumour suppressor genes. Barking up the right tree? Curr Opin Genet Dev 2010; 20: 324-329.
71. Frezza C, Pollard PJ, Gottlieb E. Inborn and acquired metabolic defects in cancer. J Mol Med (Berl) 2011; 89: 213-220.
72. Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, Pan Y, Simon MC, Thompson CB, Gottlieb E. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 2005; 7: 77-85.
73. MacKenzie ED, Selak MA, Tennant DA, Payne LJ, Crosby S, Frederiksen CM, Watson DG, Gottlieb E. Cell-permeating α-ketoglutarate derivatives alleviate pseudohypoxia in succinate dehydrogenase-deficient cells. Mol Cell Biol 2007. 27: 3282-3289.
74. Dahia PLM. Transcription association of VHL and SDH mutations link hypoxia and oxidoreductase signals in pheochromocytomas. Ann N Y Acad Sci 2006; 1073: 208-220.
75. Qin Y, Buddavarapu K, Dahia PLM. Pheochromocytomas: from genetic diversity to new paradigms. Horm Metab Res 2009; 41: 664-671.
76. Smith EH, Janknecht R, Maher LJ III. Succinate inhibition of α-ketoglutarate-dependent enzymes in a yeast model of paraganglioma. Hum Mol Genet 2007; 16: 3136-3148.
77. Chandel NS, Maltepe E, Goldwasser E, Mathieu CE, Simon MC, Schumacker PT. 1998; Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. PNAS 1998; 95: 11715-11720.
78. Guzy RD, Sharma B, Bell E, Chandel NS, Schumacker PT. Loss of the SdhB, but not the SdhA, subunit of complex II triggers reactive oxygen species-dependent hypoxia-inducible factor activation and tumorigenesis. Mol Cell Biol 2008; 28: 718-731.
79. Ishii T, Yasuda K, Akatsuka A, Hino O, Hartman PS, Ishii N. A mutation in the SDHC gene of complex II increases oxidative stress, resulting in apoptosis and tumorigenesis. Cancer Res 2005; 65: 203-209.
80. Selak MA, Duran RV, Gottlieb E. Redox stress is not essential for the pseudo-hypoxic phenotype of succinate dehydrogenase deficient cells. Biochim Biophys Acta 2006; 1757: 567-572.
81. Maxwell PH. A common pathway for genetic events leading to pheochromocytoma. Cancer Cell 2005; 8: 91-93.
82. Schlisio S, Kenchappa RS, Vredeveld LCW, George RE, Stewart R, Greulich H, Shahriari K, Nguyen NV, Pigny P, Dahia PL, Pomeroy SL, Maris JM, Look AT, Meyerson M, Peeper DS, Carter BD, Kaelin WG Jr. The kinesin KIF1Bb acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev 2008; 22: 884-893.
83. Agger K, Christensen J, Cloos PAC, Helin K. The emerging functions of histone demethylases. Curr Opin Genet Dev 2008; 18: 159-168.
84. Cervera AM, Bayley JP, Devilee P, McCreath KJ. Inhibition of succinate dehydrogenase dysregulates histone modification in mammalian cells. Mol Cancer 2009; 8: 89.
85. Pollard PJ, Brière JJ, Alam NA, Barwell J, Barclay E, Wortham NC, Hunt T, Mitchell M, Olpin S, Moat SJ, Hargreaves IP, Heales SJ, Chung YL, Griffiths JR, Dalgleish A, McGrath JA, Gleeson MJ, Hodgson SV, Poulsom R, Rustin P, Tomlinson IPM. Accumulation of Krebs cycle intermediates and over-expression of HIF-1α in tumours which result from germline FH and SDH mutations. Hum Mol Genet 2005; 14: 2231-2239.
86. Pithukpakorn M, Toro JR. Hereditary leiomyomatosis and renal cell cancer. In: Pagon RA, Bird TD, Dolan CR, Stephens K, editors. Gene Reviews [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2006 Jul 31 [updated 2010 Nov 02].
87. Isaacs JS, Jung YJ, Mole DR, Lee S, Torres-Cabala C, Chung YL, Merino M, Trepel J, Zbar B, Toro J, Ratcliffe PJ, Linehan WM, Neckers L. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 2005; 8: 143-153.
88. Lehtonen HJ, Blanco I, Piulats JM, Herva R, Launonen V, Aaltonen LA. Conventional renal cancer in a patient with fumarate hydratase mutation. Hum Pathol 2007; 38: 793-796.
89. Bayley JP, Launonen V, Tomlinson IPM. The FH mutation database: an online database of fumarate hydratase mutations involved in the MCUL (HLRCC) tumor syndrome and congenital fumarase deficiency. BMC Med Genet 2008; 9: 20.
90. Gottlieb E, Tomlinson IPM. Mitochondrial tumour suppressors: a genetic and biochemical update. Nat Rev Cancer 2005; 5: 857-866.
91. Pollard PJ, Spencer-Dene B, Shukla D, Howarth K, Nye E, El-Bahrawy M, Deheragoda M, Joannou M, McDonald S, Martin A, Igarashi P, Varsani-Brown S, Rosewell I, Poulsom R, Maxwell P, Stamp GW, Tomlinson IPM. Targeted inactivation of Fh1 causes proliferative renal cyst development and activation of the hypoxic pathway. Cancer Cell 2007; 11: 311-319.
92. Ashrafian H, O'Flaherty L, Adam J, Steeples V, Chung YL, East P, Vanharanta S, Lehtonen H, Nye E, Hatipoglu E, Miranda M, Howarth K, Shukla D, Troy H, Griffiths J, Spencer-Dene B, Yusuf M, Volpi E, Maxwell PH, Stamp G, Poulsom R, Pugh CW, Costa B, Bardella C, Di Renzo MF, Kotlikoff MI, Launonen V, Aaltonen L, El-Bahrawy M, Tomlinson I, Pollard PJ. Expression profiling in progressive stages of fumarate-hydratase deficiency: the contribution of metabolic changes to tumorigenesis. Cancer Res 2010. 70: 9153-9165.
93. Xie H, Valera VA, Merino MJ, Amato AM, Signoretti S, Linehan WM, Sukhatma VP, Seth P. LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer (HLRCCC). Mol Cancer Ther 2009; 8: 626-635.
94. O'Flaherty L, Adam J, Heather LC, Zhdanov AV, Chung YL, Miranda MX, Croft J, Olpin S, Clarke K, Pugh CW, Griffiths J, Papkovsky D, Ashrafian H, Ratcliffe PJ, Pollard PJ. Dysregulation of hypoxia pathways in fumarate hydratase-deficient cells is independent of mitochondrial metabolism. Hum Mol Genet 2010; 19: 3844-3851.
95. Sass E, Blachinsky E, Karniely S, Pines O. Mitochondrial and cytosolic isoforms of yeast fumarase are derivatives of a single translation product and have identical amino termini. J Biol Chem 2001; 276: 46111-46117.
96. Sudarshan S, Sourbier C, Kong HS, Block K, Valera Romero VA, Yang Y, Galindo C, Mollapour M, Scroggins B, Goode N, Lee MJ, Gourlay CW, Trepel J, Linehan WM, Neckers L. Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1a stabilization by glucose-dependent generation of reactive oxygen species. Mol Cell Biol 2009; 29: 4080-4090.
97. Yang Y, Valera VA, Padilla-Nash HM, Sourbier C, Vocke CD, Vira MA, Abu-Asab MS, Bratslavsky G, Tsokos M, Merino MJ, Pinto PA, Srinivasan R, Ried T, Neckers L, Linehan WM. UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer. Cancer Genet Cytogenet 2010; 196: 45-55.
98. Lau A, Villeneuve NF, Sun Z, Wong PK, Zhang DD. Dual roles of Nrf2 in cancer. Pharmacol Res 2008; 58: 262-70.
99. Yogev O, Yogev O, Singer E, Shaulian E, Goldberg M, Fox TD, Pines O. 2010. Fumarase: a mitochondrial metabolic enzyme and a cytosolic/nuclear component of the DNA damage response. PLoS Biol, 8: e1000328.
100. Tong WH, Sourbier C, Kovtunovych G, Jeong SY, Vira M, Ghosh M, Romero VV, Sougrat R, Vaulont S, Viollet B, Kim YS, Lee S, Trepel J, Srinivasan R, Bratslavsky G, Yang Y, Linehan WM, Rouault TA. The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels. Cancer Cell 2011; 20: 315-327.
101. Frezza C, Zheng L, Folger O, Rajagopalan KN, Mac-Kenzie ED, Jerby L, Micaroni M, Chaneton B, Adam J, Hedley A, Kalna G, Tomlinson IPM, Pollard PJ, Watson DG, Deberadinis RJ, Shlomi T, Ruppin E, Gottlieb E. Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase. Nature 2011; 477: 225-228.
102. Piruat JI, Pintado CO, Ortega-Saenz P, Roche M, Lopez-Barneo J. The mitochondrial SDHD gene is required for early embryogenesis, and its partial deficiency results in persistent carotid body glomus cell activation with full responsiveness to hypoxia. Mol Cell Biol 2004; 24: 10933-10940.
103. Nakada C, Tsukamoto Y, Matsuura K, Nguyen TL, Hijiya N, Uchida T, Sato F, Mimata H, Seto M, Moriyama M. Overexpression of miR-210, a downstream target of HIF-1α, causes centrosome amplification in renal carcinoma cells. J Pathol 2011; 224: 280-288.
104. Raimundo N, Baysal BE, Shadel GS. Revisiting the TCA cycle: signaling to tumor formation. Trends Mol Med 2011; 17: 641-649.
105. Yamasaki T, Tran TAT, Oz OK, Raj GV, Schwarz RE, DeBeradinis RJ, Zhang X, Brugarolas J. Exploring a glycolytic inhibitor for the treatment of an FH-deficient type-2 papillary RCC. Nat Rev Urol 2011; 8: 165-171.
106. Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene 2006; 25: 4633-4646.
107. Michelakis ED, Webster L, Mackey JR. Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer 2008; 99: 989-994.
108. Berkson BM, Rubin DM, Berkson AJ. Revisiting that ALA/N (alpha-lipoic acid/low-dose naltrexone) protocol for people with metastatic and nonmetastatic pancreatic cancer: a report of 3 new cases. Integr Cancer Ther 2009; 8: 416-422.
109. Schwartz L, Abolhassani M, Guais A, Sanders E, Steyaert JM, Campion F, Israel M. 2009. A combination of alpha lipoic acid and calcium hydroxylcitrate is efficient against mouse cancer models: preliminary results. Oncol Rep 2009; 23: 1407-1416.
110. Abolhassani M, Guais A, Sanders E, Campion F, Fichtner I, Bonte J, Baronzio G, Fiorentini G, Israel M, Schwartz L. Screening of well-established drugs targeting cancer metabolism: reproducibility of the efficacy of a highly effective drug combination in mice. Invest New Drugs, 2011;Jun 9. [Epub ahead of print].
111. Franovic A, Holterman CE, Payette J, Lee S. Human cancers converge at the HIF-2α oncogenic axis. PNAS 2009; 106: 21306-21311.